1. Academic Validation
  2. Identification of potent inhibitors of the sortilin-progranulin interaction

Identification of potent inhibitors of the sortilin-progranulin interaction

  • Bioorg Med Chem Lett. 2020 Sep 1;30(17):127403. doi: 10.1016/j.bmcl.2020.127403.
Shawn J Stachel 1 Anthony T Ginnetti 2 Scott A Johnson 3 Paige Cramer 4 Yi Wang 5 Marina Bukhtiyarova 5 Daniel Krosky 5 Craig Stump 2 Danielle M Hurzy 2 Kelly-Ann Schlegel 2 Andrew J Cooke 2 Samantha Allen 5 Gregory O'Donnell 6 Michael Ziebell 6 Gopal Parthasarathy 3 Krista L Getty 6 Thu Ho 6 Yangsi Ou 5 Aneta Jovanovska 5 Steve S Carroll 5 Mark Pausch 5 Kevin Lumb 6 Scott D Mosser 5 Bhavya Voleti 4 Daniel J Klein 3 Stephen M Soisson 3 Celina Zerbinatti 4 Paul J Coleman 2
Affiliations

Affiliations

  • 1 Department of Medicinal Chemistry, Merck & Co. Inc., PO Box 4, West Point, PA 19486, USA. Electronic address: [email protected].
  • 2 Department of Medicinal Chemistry, Merck & Co. Inc., PO Box 4, West Point, PA 19486, USA.
  • 3 Department of Chemistry and Structural Chemistry, Merck & Co. Inc., PO Box 4, West Point, PA 19486, USA.
  • 4 Department of Neuroscience, Merck & Co. Inc., PO Box 4, West Point, PA 19486, USA.
  • 5 Department of Pharmacology, Merck & Co. Inc., PO Box 4, West Point, PA 19486, USA.
  • 6 Screening and Protein Science, Merck & Co. Inc., PO Box 4, West Point, PA 19486, USA.
Abstract

High-throughput screening methods have been used to identify two novel series of inhibitors that disrupt progranulin binding to sortilin. Exploration of structure-activity relationships (SAR) resulted in compounds with sufficient potency and physicochemical properties to enable co-crystallization with sortilin. These co-crystal structures supported observed SAR trends and provided guidance for additional avenues for designing compounds with additional interactions within the binding site.

Keywords

Progranulin; Protein-protein interaction inhibitor; Sortilin; Structure activity relationship.

Figures
Products